Moberg Pharma granted U.S. patent relating to improved dosing of MOB-015

Impact · against what's priced in

Moberg Pharma gains a significant strategic advantage in the US market with a new dosing patent extending to 2041. This strengthens the company's IP moat and provides a concrete foundation for planned Phase 3 studies to support FDA approval in the world's largest onychomycosis market.

MOB+0.50: No priced-in read yet
In context: The granting of a US patent for improved dosing of MOB-015 through December 2041 provides critical intellectual property protection in the largest global market for the condition and supports future FDA approval efforts.
Read from the article alone

Moberg Pharma granted U.S. patent relating to improved dosing of MOB-015

healthcare
biotech
MOB
clinical trials
drug delivery
fda
patent
pharma
uspto

Search tags

Moberg Pharma granted U.S. patent relating to improved dosing of MOB-015

What matters in this story

Precigen Gears Up to Report Q3 Earnings: What Can Investors Expect?

Moberg Pharma granted U.S. patent relating to improved dosing of MOB-015

What matters in this story

Precigen Gears Up to Report Q3 Earnings: What Can Investors Expect?

How each ticker is affected

Track these names every morning.

BMY Up 3% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock?

Eli Lilly Jumped 6% After Earnings. It's Up 68% in a Year.

Tiziana's experimental MS treatment meets main goals in mid-stage study

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Completes New Extraction of IBEX011, Its Naturally Derived Ibogaine Drug Candidate, and Commences Stability Testing

Moberg Pharma granted U.S. patent relating to improved dosing of MOB-015

What matters in this story

Next reads from the same story arc

Precigen Gears Up to Report Q3 Earnings: What Can Investors Expect?

Moberg Pharma granted U.S. patent relating to improved dosing of MOB-015

What matters in this story

Next reads from the same story arc

Precigen Gears Up to Report Q3 Earnings: What Can Investors Expect?

How each ticker is affected

Track these names every morning.

BMY Up 3% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock?

Eli Lilly Jumped 6% After Earnings. It's Up 68% in a Year.

Tiziana's experimental MS treatment meets main goals in mid-stage study

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Completes New Extraction of IBEX011, Its Naturally Derived Ibogaine Drug Candidate, and Commences Stability Testing